Mucormycosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Mucormycosis has limited data which outlines the [[epidemiology]] and [[demographics]] of the [[disease]]. It is known to have a high [[case fatality rate | Mucormycosis has limited data which outlines the [[epidemiology]] and [[demographics]] of the [[disease]]. It is known to have a high [[case fatality rate]]. | ||
==Epidemiology and Demographics | ==Epidemiology and Demographics<ref name="pmid16080086">{{cite journal |vauthors=Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ |title=Epidemiology and outcome of zygomycosis: a review of 929 reported cases |journal=Clin. Infect. Dis. |volume=41 |issue=5 |pages=634–53 |year=2005 |pmid=16080086 |doi=10.1086/432579 |url=}}</ref> == | ||
*Mucormycosis has limited national data available in the United States .<ref name="urlMucormycosis Statistics | Mucormycosis | Fungal Diseases | CDC">{{cite web |url=https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html#eight |title=Mucormycosis Statistics | Mucormycosis | Fungal Diseases | CDC |format= |work= |accessdate=}}</ref> | *Mucormycosis has limited national data available in the United States .<ref name="urlMucormycosis Statistics | Mucormycosis | Fungal Diseases | CDC">{{cite web |url=https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html#eight |title=Mucormycosis Statistics | Mucormycosis | Fungal Diseases | CDC |format= |work= |accessdate=}}</ref> | ||
*The data available is population-based, varies according to the geographic region and is reported over a time period. | *The data available is population-based, varies according to the geographic region and is reported over a time period. | ||
| Line 25: | Line 23: | ||
*There is no racial predilection for mucormycosis. | *There is no racial predilection for mucormycosis. | ||
===Gender=== | ===Gender<ref name="pmid16080086" />=== | ||
* There is no gender predilection for mucormycosis. | * There is no gender predilection for mucormycosis. | ||
*Mucormycosis is frequently a life-threatening infection. A review of published mucormycosis cases found an overall [[Mortality rate|all-cause mortality rate]] of 54000 per 100,000 indiviudals. | *Mucormycosis is frequently a life-threatening infection. A review of published mucormycosis cases found an overall [[Mortality rate|all-cause mortality rate]] of 54000 per 100,000 indiviudals. | ||
*The overall [[case fatality rate]] for patients with [[Diabetes mellitus|diabetes]] is 44000 100,000 patients. | *The overall [[case fatality rate]] for patients with [[Diabetes mellitus|diabetes]] is 44000 100,000 patients. | ||
Revision as of 01:45, 19 June 2017
|
Mucormycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
Mucormycosis has limited data which outlines the epidemiology and demographics of the disease. It is known to have a high case fatality rate.
Epidemiology and Demographics[1]
- Mucormycosis has limited national data available in the United States .[2]
- The data available is population-based, varies according to the geographic region and is reported over a time period.
- The prevalence is 36000 per 100,000 patients for diabetics.
- The prevalence of mucormycosis for individuals for no underlying condition is 19000 per 100,000 individuals.
- The prevalence of mucormycosis for patients with malignancy is 17000 per 100,000 patients.
- The prevalence rate of mucormycosis infection was generally 4200 per 100,000 patients of hematologic malignancies in a study conducted in Iran.[3]
Incidence
- A population-based surveillance study in San Francisco, California, from 1992 to 1993 revealed that the annual incidence of mucormycosis was 1.7 cases per 100,000 individuals (roughly 500 cases per year).[4]
- A more recent study in a more general population in Spain found a lower incidence 0.43 cases per 100,000 individuals.[5]
Age
- Extremes of age predispose an individual to mucormycosis infection.
Race
- There is no racial predilection for mucormycosis.
Gender[1]
- There is no gender predilection for mucormycosis.
- Mucormycosis is frequently a life-threatening infection. A review of published mucormycosis cases found an overall all-cause mortality rate of 54000 per 100,000 indiviudals.
- The overall case fatality rate for patients with diabetes is 44000 100,000 patients.
- The overall case fatality rate for individuals with no underlying condition is 35000 per 100,000 individuals.
- The overall case fatality rate for patients with malignancy like acute myeloid leukemia and myelodysplastic syndrome is 66000 per 100,000 patients.
Seasonal Variation
- Data suggests that there is a seasonal variation among patients acquiring mucormycosis infection with a peak during the Autumn season.[6][7]
Reference
- ↑ 1.0 1.1 Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ (2005). "Epidemiology and outcome of zygomycosis: a review of 929 reported cases". Clin. Infect. Dis. 41 (5): 634–53. doi:10.1086/432579. PMID 16080086.
- ↑ "Mucormycosis Statistics | Mucormycosis | Fungal Diseases | CDC".
- ↑ Noorifard M, Sekhavati E, Jalaei Khoo H, Hazraty I, Tabrizi R (2015). "Epidemiology and clinical manifestation of fungal infection related to Mucormycosis in hematologic malignancies". J Med Life. 8 (Spec Iss 2): 32–37. PMC 5327702. PMID 28255394.
- ↑ Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL (1998). "The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance". Clin. Infect. Dis. 27 (5): 1138–47. PMID 9827260.
- ↑ Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Gadea I, Bouza E (2007). "Impact of zygomycosis on microbiology workload: a survey study in Spain". J. Clin. Microbiol. 45 (6): 2051–3. doi:10.1128/JCM.02473-06. PMC 1933097. PMID 17392438.
- ↑ Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, Berkowicz M, Keller N, Kronenberg J (2002). "Rhino-orbital and rhino-orbito-cerebral mucormycosis". Otolaryngol Head Neck Surg. 127 (1): 22–31. doi:10.1067/mhn.2002.126587. PMID 12161726.
- ↑ Funada H, Matsuda T (1996). "Pulmonary mucormycosis in a hematology ward". Intern. Med. 35 (7): 540–4. PMID 8842759.